Reuters logo
PTC shares soar on EU backing for muscular dystrophy drug
May 23, 2014 / 12:10 PM / 3 years ago

PTC shares soar on EU backing for muscular dystrophy drug

LONDON (Reuters) - Shares in U.S. biotech company PTC Therapeutics more than doubled in premarket dealings on Friday after European regulators recommended a conditional marketing authorization for Translarna, its drug for Duchenne muscular dystrophy.

European Medicines Agency experts had adopted a negative opinion on the drug in January.

Conditional marketing authorization is an early access mechanism for medicines that address an unmet medical need for patients suffering from life-threatening diseases, even if comprehensive clinical data are not yet available.

Reporting by Ben Hirschler, Editing by Paul Sandle

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below